Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions.
about
T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and PerspectivesRituximab in primary Sjögren's syndrome: a ten-year journey.Increased Expression of TGF-β Signaling Components in a Mouse Model of Fibrosis Induced by Submandibular Gland Duct Ligation.Liver Diseases and AutoimmunitySignificance of Interleukin-6/STAT Pathway for the Gene Expression of REG Iα, a New Autoantigen in Sjögren's Syndrome Patients, in Salivary Duct Epithelial Cells.Antibodies against carbamylated proteins are present in primary Sjögren's syndrome and are associated with disease severity.Do Cyclosporine A, an IL-1 Receptor Antagonist, Uridine Triphosphate, Rebamipide, and/or Bimatoprost Regulate Human Meibomian Gland Epithelial Cells?Autophagy inhibition augments resveratrol-induced apoptosis in Ishikawa endometrial cancer cells.Oral Rehabilitation and Management for Secondary Sjögren's Syndrome in a Child.In vitro suppression of immune responses using monocyte-derived tolerogenic dendritic cells from patients with primary Sjögren's syndrome.Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis.A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.Renal involvement in primary Sjögren's syndrome.Effect of Systemic Infliximab Therapy in Patients with Sjögren's Syndrome.Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study.Co-culture system of human salivary gland epithelial cells and immune cells from primary Sjögren's syndrome patients: an in vitro approach to study the effects of Rituximab on the activation of the Raf-1/ERK1/2 pathway.
P2860
Q26859226-72091B15-26A5-442F-A0CD-C432EDDD4E7DQ34432465-227D5651-EC4C-4131-9FC8-C7D71FB6A4E4Q35587144-AC913AC5-3097-4224-A396-5DB84DC86781Q35906041-26B71CCB-F451-4817-A2D1-149800A2522FQ36060629-96F6D242-B7F5-4932-8AB0-B11FB8639466Q37156391-A75A6FF1-0C0C-4702-83A3-B62FFA0400B6Q37242107-B924A65E-697F-47EA-98B4-0771BD413CAFQ37287535-F0345189-051D-4159-974F-1FD65692F480Q37492549-210D1C92-14AF-4ECB-AB89-838EC11F3A44Q37689751-C5ABB328-C7D1-4EBE-84BE-688C247103E1Q38220995-2FFC0C56-D08C-4F68-8FF3-EE393D408F80Q38389487-FC8D1DEC-D241-4CD9-AC71-836C7A294320Q38526786-05B3C1EF-E54F-4412-93BE-56BF2E3A2D3FQ41592241-48AE3296-FF3D-455C-B835-3289B366DC2EQ48341665-8D7C684B-A532-45DF-8B46-280A1535BB7CQ53194059-C01E44FF-8ED5-4355-86D3-2954DA8B7A4AQ54310740-6ABBF93D-BC5B-4F6F-8340-3BA86EAD837D
P2860
Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Primary Sjögren syndrome: an u ...... options and future directions.
@en
type
label
Primary Sjögren syndrome: an u ...... options and future directions.
@en
prefLabel
Primary Sjögren syndrome: an u ...... options and future directions.
@en
P2860
P50
P1476
Primary Sjögren syndrome: an u ...... options and future directions
@en
P2093
Albert Bové
P2860
P304
P356
10.1517/14656566.2013.767333
P407
P577
2013-01-25T00:00:00Z